Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs DigitalOcean Holdings Inc (DOCN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs DigitalOcean Holdings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.64 (market cap $29.60B), while DigitalOcean Holdings Inc trades at $133.8 (market cap $14.21B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.1× DigitalOcean Holdings Inc's market cap, and DigitalOcean Holdings Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | DOCN | |
|---|---|---|
Market Cap | $29.60B | $14.21B |
Sector | Health | Technology |
52-Week High | $491.22 | $181.29 |
52-Week Low | $205.48 | $29.99 |
Enterprise Value | $27.56B | $14.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
DigitalOcean (DOCN) trades at $129.73, up 4.49% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains a bullish technical outlook with support at $124 and resistance at $135. Revenue growth accelerated to 29% year-over-year in Q2 2026, driven by surging AI-native cloud demand, while maintaining robust 40% adjusted EBITDA margins. Analyst consensus remains strongly positive with a $173.71 price target representing 34% upside potential.
DOCN presents compelling growth exposure to the AI infrastructure boom with accelerating revenue and strong profitability, though elevated valuation multiples (P/E 54.94) and high leverage ($1.49B debt) warrant caution. The company's strategic positioning in AI inference workloads and raised 2026 guidance support continued upside, but investors should monitor competitive pressures and execution risks in the rapidly evolving cloud market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →
